Rethinking radiotherapy may boost immunotherapy for pancreatic cancer

Pancreatic cancer stands out as an exceptionally aggressive form of cancer, often displaying a poor prognosis even when detected at an early, localized stage. A collaborative effort from researchers at GIGA, Liège University Hospital, Gustave Roussy, and Fox Chase Cancer Center, published in Nature Reviews Gastroenterology & Hepatology, offers a fresh perspective on treating this challenging disease.

Instead of simply using radiotherapy to kill cancer cells, the review suggests that it may function as a means to boost the immune system's ability to fight cancer, thus improving the effectiveness of immunotherapy. Led by Dr. Gilles Colin and Dr. Pierre Foidart, the review delves into the latest research advances, aiming to understand how radiotherapy can influence the antitumor immune responses, thereby paving the way for better combinations with immunotherapy to minimize metastatic relapse rates.

Pancreatic cancer's dense tumor microenvironment, which includes a high amount of stromal cells and mechanisms that naturally suppress immune cell activity, poses a significant challenge. This environment makes immunotherapies less effective against pancreatic cancer. Moreover, current radiotherapy treatments have yielded modest results, delivered according to standard protocols.

The researchers underline, however, that radiotherapy possesses biological properties that have not been fully utilized. When administered under precise conditions, it can enhance the visibility of cancer cells to the immune system, stimulate the activity of immune cells, and modify the tumor microenvironment to promote antitumor immunity.

Determining the optimal parameters for radiotherapy—such as radiation dose, fractionation, treatment sequencing, precision of irradiation, and target volume selection—becomes crucial in future therapeutic strategies. The review also explores various strategies that are being examined in preclinical and clinical trials. Some strategies focus on more targeted and tolerable forms of radiotherapy, while others aim to pair radiotherapy with advanced forms of immunotherapy, therapeutic vaccines, or treatments that can reshape the tumor microenvironment.

Additionally, the review highlights the development of inhibitors targeting pathways crucial to pancreatic cancer, particularly those related to KRAS, a protein that's frequently mutated in this disease. To maximize the chances of success, the authors emphasize the need to understand how different delivery parameters of radiotherapy affect the immune response.

Future research will also depend on identifying patients who are more likely to benefit from these combined therapies. This could be achieved through the development of predictive biomarkers, analysis of circulating tumor DNA, and the implementation of adaptive clinical trial designs, which could help personalize treatment and refine combination strategies.

Despite its challenges, pancreatic cancer remains a significant focus of oncological research. This new perspective on radiotherapy not only offers a fresh approach to treating this disease but also paves the way for more effective therapies. By integrating radiotherapy, immunotherapy, precision medicine, and technological advancements, researchers hope to overcome the cancer's resistance mechanisms, improve local disease control, and potentially extend survival rates for pancreatic cancer patients.